Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Active not recruiting 8Recruiting 4Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 18Biopsy 17Cyclophosphamide 6venetoclax 5Vincristine 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Bevacizumab 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Radiation 3Injections 3Cetuximab 3trastuzumab deruxtecan 2olaparib 2iadademstat 2fludarabine 2durvalumab 2cemiplimab 2Tacrolimus 2Standard of Care 2Sirolimus 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Peripheral Blood Stem Cell Transplantation × 90 days × Clear all
NCT02333162 2026-03-30

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

University of Chicago

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡